|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 366.89 PKR | +2.14% |
|
-2.74% | -5.87% |
Company Valuation: GlaxoSmithKline Pakistan Limited
Data adjusted to current consolidation scope
| Fiscal Period: December | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| Market Cap 1 | 126,403 | 124,132 | 116,842 | - | - |
| Change | - | -1.8% | -5.87% | - | - |
| Enterprise Value (EV) | 126,403 | 124,132 | 116,842 | 116,842 | 116,842 |
| Change | - | -1.8% | -5.87% | 0% | 0% |
| P/E | 19.3x | 12.4x | 10.6x | 9.08x | 8.1x |
| PBR | - | 3.69x | 2.69x | 2.32x | 2.03x |
| PEG | - | 0.2x | 1.11x | 0.5x | 0.7x |
| Capitalization / Revenue | - | 1.88x | 1.7x | 1.57x | 1.43x |
| EV / Revenue | - | 0x | 1.7x | 1.57x | 1.43x |
| EV / EBITDA | - | - | - | - | - |
| EV / EBIT | - | - | - | - | - |
| EV / FCF | - | - | - | - | - |
| FCF Yield | - | - | - | - | - |
| Dividend per Share 2 | - | 17 | 18.56 | 20.81 | 23.5 |
| Rate of return | - | 4.36% | 5.06% | 5.67% | 6.41% |
| EPS 2 | 20.52 | 31.48 | 34.48 | 40.4 | 45.27 |
| Distribution rate | - | 54% | 53.8% | 51.5% | 51.9% |
| Net sales 1 | - | 65,901 | 68,813 | 74,577 | 81,779 |
| EBITDA | - | - | - | - | - |
| EBIT | - | - | - | - | - |
| Net income 1 | 6,536 | 10,025 | 10,490 | 12,420 | 14,268 |
| Net Debt | - | - | - | - | - |
| Reference price 2 | 396.91 | 389.78 | 366.89 | 366.89 | 366.89 |
| Nbr of stocks (in thousands) | 318,467 | 318,467 | 318,467 | - | - |
| Announcement Date | 3/24/25 | 3/26/26 | - | - | - |
1PKR in Million2PKR
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
| 10.64x | - | - | 5.06% | 420M | ||
| 32.86x | 12x | 24.39x | 0.61% | 1,006B | ||
| 26.17x | 6.03x | 16.39x | 2.18% | 589B | ||
| 30.87x | 7.21x | 14.74x | 2.85% | 430B | ||
| 17.87x | 4.45x | 10.93x | 2.99% | 331B | ||
| 23.29x | 4.86x | 13.76x | 1.8% | 288B | ||
| 21.56x | 5.56x | 13.49x | 2.84% | 285B | ||
| 13.98x | 5.17x | 10.65x | 3.6% | 213B | ||
| 22.94x | 6.13x | 10.71x | 2.86% | 190B | ||
| -44.37x | 5.36x | 29.56x | 2.62% | 154B | ||
| Average | 15.58x | 6.31x | 16.07x | 2.74% | 348.62B | |
| Weighted average by Cap. | 23.24x | 7.53x | 17.44x | 2.05% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- GLAXO Stock
- Valuation GlaxoSmithKline Pakistan Limited
Select your edition
All financial news and data tailored to specific country editions
















